Gilead gets Sovaldi patent approval in India despite opposition

Gilead has been granted a patent for its hepatitis C drug Sovaldi (sofosbuvir) in India, despite concerns over the cost of the drug.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Asia

MSF challenges Gilead patent application in China

21 December 2017 Médecins Sans Frontières has challenged a patent application filed by Gilead in China, claiming that the rejection of the patent would “pave the way towards the availability of affordable generic versions”.

Asia

Médecins Sans Frontières fears Pfizer’s monopoly over pneumonia vaccine

15 March 2016 Activist organisation Médecins Sans Frontières has challenged Pfizer’s patent application covering the pneumococcal conjugate vaccine on the grounds that it is obvious.

Asia

MSF urges Indian Patent Office to reject Gilead Sovaldi patent

2 March 2016 Médecins Sans Frontières has urged the Indian Patent Office to reject a Gilead Sciences patent application covering Sovaldi.